Nilotinib (AMN-107)

Catalog No.S1033

Nilotinib (AMN-107) Chemical Structure

Molecular Weight(MW): 529.52

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 60 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
Features A selective inhibitor of native and mutant Bcr-Abl.
Targets
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
In vitro

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NW\3WoVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG1UHhCUUN3ME2wMlAxODF2NDFOwG0> MWfTRW5ITVJ?
KU812 NXfpZmhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq3XoNGUUN3ME2wMlAxOjR6IN88US=> NVrVWplNW0GQR1XS
EM-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKwb2VWUUN3ME2wMlAxPDFizszN M1HGT3NCVkeHUh?=
LAMA-84 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT5TWM2OD1yLkCwOFkh|ryP MUTTRW5ITVJ?
MEG-01 NYjKZ417T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHGe2pKSzVyPUCuNFA5OjhizszN NXP6VWZiW0GQR1XS
BV-173 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLQOm9KSzVyPUCuNFExQDlizszN NVzTN5VLW0GQR1XS
KASUMI-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLYTWM2OD1yLkCyOFE{KM7:TR?= Ml22V2FPT0WU
NB7 NI\p[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XYO2lEPTB;MD6xN|Q{QSEQvF2= MknEV2FPT0WU
BHT-101 NHfZXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7nc3ZRUUN3ME2wMlY1OjZ|IN88US=> M{i1T3NCVkeHUh?=
CGTH-W-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwNkS4O{DPxE1? M3KzWnNCVkeHUh?=
HMV-II Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DsRmlEPTB;MD63OFg4PCEQvF2= MmfEV2FPT0WU
NKM-1 NFyySFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfqWIFKUUN3ME2wMlkxOTVizszN NELhd|dUSU6JRWK=
LB2241-RCC MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwMEKyNlgh|ryP NFjtbGhUSU6JRWK=
NCI-H1703 NWLXbJBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL1b2JKSzVyPUGuNVg5PyEQvF2= MWrTRW5ITVJ?
BE-13 M4TNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwMke0NVYh|ryP M4TZ[XNCVkeHUh?=
ACN M{Py[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K5ZWlEPTB;MT61OVA4PyEQvF2= MXjTRW5ITVJ?
A204 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y5bmlEPTB;MT61O|IxPSEQvF2= NIPrZZNUSU6JRWK=
HOP-62 NWfBXWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3tTJdKSzVyPUGuPFIxPzdizszN NF\kWHJUSU6JRWK=
H9 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\O[3FKSzVyPUKuO|M4QTNizszN MUDTRW5ITVJ?
HCC1806 NInmV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwN{SzNlch|ryP NFfMUoRUSU6JRWK=
NOS-1 NW\m[495T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwOEexNFIh|ryP MYTTRW5ITVJ?
RS4-11 Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTkU5ZKSzVyPUKuPVA3OjNizszN NEPsWIRUSU6JRWK=
JAR M1nqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwOUKwPFQh|ryP MnG3V2FPT0WU
T98G MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPKfWp6UUN3ME2zMlAyOzF|IN88US=> MUnTRW5ITVJ?
NCI-SNU-1 NVrFSZFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNwNECwPVIh|ryP M2HBZnNCVkeHUh?=
SK-MEL-1 NGLlbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfMfGtKSzVyPUOuOFMxOjlizszN M4jmcnNCVkeHUh?=
L-363 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSyPHpKSzVyPUOuOlEyODdizszN NYf2PWxVW0GQR1XS
SW982 NIn0XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XaVmlEPTB;Mz62OFE3QSEQvF2= Mn\xV2FPT0WU
HT-1080 M3PUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNwOUG3O|Uh|ryP MnzCV2FPT0WU
G-402 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwM{GyNFMh|ryP NXy3[4M2W0GQR1XS
HOS M4LRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nxTWlEPTB;ND64NFI5OiEQvF2= M3X2OnNCVkeHUh?=
SK-NEP-1 NEjLbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf5XZZKSzVyPUSuPFMyQTFizszN M{DDUXNCVkeHUh?=
HAL-01 M1\Cbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRwOEiyOFIh|ryP MVTTRW5ITVJ?
SBC-1 NXnPW3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXtVpNKSzVyPUSuPVA6ODdizszN M2LPW3NCVkeHUh?=
CTV-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPkWWRqUUN3ME21MlQ5QTN6IN88US=> M3L1dnNCVkeHUh?=
LCLC-103H M4rVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\NTWM2OD13Lke3OFcyKM7:TR?= MkPaV2FPT0WU
RVH-421 NFLkNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfTRmJEUUN3ME21Mlc4PTN4IN88US=> NIHyRo5USU6JRWK=
K-562 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DqeWlEPTB;NT65NFM3KM7:TR?= NETn[HVUSU6JRWK=
CAL-33 NGDwc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DDd2lEPTB;Nj6zNVM2QSEQvF2= NV\5dY92W0GQR1XS
MDA-MB-361 NGO0Oo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTZwM{O2PVkh|ryP NG[y[nlUSU6JRWK=
IGROV-1 M4fIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH30bGhKSzVyPU[uOFcyQTFizszN NILRdm9USU6JRWK=
NY M3fCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTiTWM2OD14LkWzOVk6KM7:TR?= MoTPV2FPT0WU
Ramos-2G6-4C10 NEfuPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTZwNk[5N|Eh|ryP NFj0NYpUSU6JRWK=
HuO9 M3zRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDXN|F{UUN3ME22Mlc{QTZ2IN88US=> Mn7CV2FPT0WU
MS-1 NH:1SWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTdwMUG5OVMh|ryP NUL3fmgyW0GQR1XS
RPMI-8226 M3zWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjnVGdKSzVyPUeuNlgzQDdizszN MYnTRW5ITVJ?
HDLM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33PemlEPTB;Nz60NFE1QSEQvF2= MmTzV2FPT0WU
D-566MG NFPiWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTdwNEexOVUh|ryP M4f6XnNCVkeHUh?=
SK-MEL-24 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHmXnMzUUN3ME23MlY{Ozl{IN88US=> MXvTRW5ITVJ?
COLO-679 NHvFZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfqflc5UUN3ME23Mlk5PjdzIN88US=> NVvPUG1pW0GQR1XS
EW-13 M3nG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPtXGxKSzVyPUiuN|IxPTRizszN NETCRVFUSU6JRWK=
A388 NUnn[5ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRThwM{i0PFEh|ryP MXLTRW5ITVJ?
UM-UC-3 MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRThwNEO5OVYh|ryP M1vZdnNCVkeHUh?=
NUGC-3 NIT6e2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3ObpRKSzVyPUiuOVM2QDJizszN NITNUnFUSU6JRWK=
COLO-668 NHvS[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULNSnIzUUN3ME24MlU6PDlzIN88US=> MXvTRW5ITVJ?
MOLT-4 NXPBSIl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GwRmlEPTB;OD62NlM2OyEQvF2= NFvKO|VUSU6JRWK=
D-423MG NXTqZ2xsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrjTWM2OD16LkizO|U3KM7:TR?= NXPBd4tsW0GQR1XS
CTB-1 NEO3bnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRThwOEexNlgh|ryP MUnTRW5ITVJ?
BCPAP MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jzSmlEPTB;OT6wNlU3OiEQvF2= MUTTRW5ITVJ?
GCT MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTlwMEm4N|Eh|ryP M1fYVXNCVkeHUh?=
ACHN MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPYelRKSzVyPUmuNlM3OzJizszN MonDV2FPT0WU
KYSE-520 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\1Zm5KSzVyPUmuN|M1QDJizszN MXPTRW5ITVJ?
LB771-HNC NYrnPIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoryTWM2OD17Lke2OFk4KM7:TR?= NGj3bYdUSU6JRWK=
MLMA NIK1dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFyLkCxN|Ih|ryP MVvTRW5ITVJ?
HEC-1 NUnMSYdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zrW2lEPTB;MUCuNlgxPCEQvF2= NFfpXGNUSU6JRWK=
HL-60 M{[5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHyTWM2OD1zMD62PFU{KM7:TR?= MWTTRW5ITVJ?
A101D M1zIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\HNIJKSzVyPUGwMlg6OjNizszN MlXyV2FPT0WU
A2058 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqxc3VKSzVyPUGwMlkzPDVizszN NW\YeHhIW0GQR1XS
KARPAS-45 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYizO3hRUUN3ME2xNU4xPjN3IN88US=> M2DxbnNCVkeHUh?=
697 NIPZPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTXZ2ZsUUN3ME2xNU4zOTBzIN88US=> M{LlS3NCVkeHUh?=
NCI-N87 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXmS|FRUUN3ME2xNU44PzNzIN88US=> NWC2WZp2W0GQR1XS
DSH1 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjMTWM2OD1zMT63PVU{KM7:TR?= MX3TRW5ITVJ?
HLE MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHiTWM2OD1zMT64PFM6KM7:TR?= MUPTRW5ITVJ?
NCI-H720 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF{Lk[4NFEh|ryP NHPHbo5USU6JRWK=
EW-3 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmruTWM2OD1zMj65N|A4KM7:TR?= Ml3mV2FPT0WU
AGS NIXoTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF|LkCzOVEh|ryP MVHTRW5ITVJ?
ES5 NVWwelV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTvTWM2OD1zMz6wOVEzKM7:TR?= M1LKPHNCVkeHUh?=
DB NXLuU3c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorKTWM2OD1zMz6zNlU3KM7:TR?= NYDRNXZvW0GQR1XS
A4-Fuk NH7Mb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln2TWM2OD1zMz60NVAzKM7:TR?= NIPmd|BUSU6JRWK=
A427 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHzTWM2OD1zMz60PVczKM7:TR?= MYnTRW5ITVJ?
MN-60 M4\ZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfBe3EzUUN3ME2xN{42QDR|IN88US=> NEDpbYdUSU6JRWK=
HCC2218 NUHLVJVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nwOWlEPTB;MUOuOVg2PiEQvF2= NVWwUWl3W0GQR1XS
MV-4-11 Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvzPYxKSzVyPUGzMlgyOzdizszN NIHIZpJUSU6JRWK=
GI-1 M1PXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnyO|dKSzVyPUG0MlEyQDRizszN Mmj1V2FPT0WU
JVM-3 NWjXemRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f1TWlEPTB;MUSuNlY2PiEQvF2= M1\iUXNCVkeHUh?=
NCI-H2029 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\zWYxKSzVyPUG0MlI4OjdizszN NFvFeJFUSU6JRWK=
TE-12 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF2Lk[wOFYh|ryP NIn6PXhUSU6JRWK=
WM-115 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fmcGlEPTB;MUWuOVY5OyEQvF2= NVL0bJI3W0GQR1XS
BB65-RCC M{i2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF4LkCyOFEh|ryP NIDINZdUSU6JRWK=
NCI-H1693 M1PEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDtTWM2OD1zNj6zPFAzKM7:TR?= Mlj3V2FPT0WU
KARPAS-299 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTF4Lk[yNFMh|ryP NV:0bppOW0GQR1XS
UACC-257 NGXsZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDjTWM2OD1zNz6wOVgzKM7:TR?= MXLTRW5ITVJ?
RKO MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PFNGlEPTB;MUeuOlQ{OyEQvF2= NEXabW5USU6JRWK=
HT-29 NFq0NYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjycnpCUUN3ME2xO{44QDh7IN88US=> Ml\lV2FPT0WU
ES7 NHX3cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rEUGlEPTB;MUiuNVEzOiEQvF2= MXvTRW5ITVJ?
DEL NGXJfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PpWWlEPTB;MUiuN|E4OiEQvF2= NHnmcopUSU6JRWK=
BT-549 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvROVFpUUN3ME2xPE41ODl{IN88US=> Mki5V2FPT0WU
NCI-H1755 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;FTWM2OD1zOD61O|I{KM7:TR?= NGPyN4dUSU6JRWK=
HCE-T M1zFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zaW2lEPTB;MUiuPFM1OSEQvF2= NIPjNIdUSU6JRWK=
LU-139 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLISI17UUN3ME2xPU4xPDV6IN88US=> M{[5b3NCVkeHUh?=
ECC10 NHq2UGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f2dmlEPTB;MUmuNlQ4PSEQvF2= NH7EPIhUSU6JRWK=
769-P M2XmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\4UIdKSzVyPUG5MlY{OzVizszN NF[x[mNUSU6JRWK=
BALL-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF7Lk[3O|Uh|ryP NXTlSHFiW0GQR1XS
LXF-289 MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSzOVlKSzVyPUG5Mlg6PzlizszN NVfuUIFIW0GQR1XS
TYK-nu MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXwcmtKSzVyPUG5Mlk{OTVizszN M3\rR3NCVkeHUh?=
NCI-H630 NX3PenBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLKTWM2OD1zOT65N|c5KM7:TR?= MoOyV2FPT0WU
EW-18 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHQTWM2OD1{MD6zPFAzKM7:TR?= MnG2V2FPT0WU
KYSE-150 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HWZ2lEPTB;MkCuO|A1PyEQvF2= NHy3UJdUSU6JRWK=
LOXIMVI MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvGTWM2OD1{MD63OVg3KM7:TR?= M1jKe3NCVkeHUh?=
HuP-T3 NWrqWlBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TnR2lEPTB;MkGuNFg2OiEQvF2= MY\TRW5ITVJ?
MFE-280 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\pWGlEPTB;MkGuOVY4QSEQvF2= NVG2OJR5W0GQR1XS
SK-OV-3 M3Txcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DMb2lEPTB;MkGuPFQxQCEQvF2= NHjxOYlUSU6JRWK=
QIMR-WIL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\XOGlEPTB;MkKuNFQ4QCEQvF2= M1PkWXNCVkeHUh?=
NCI-H69 NE\pR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PBZmlEPTB;MkKuOFI6QSEQvF2= MWTTRW5ITVJ?
TE-5 NH;SOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG4bodyUUN3ME2yNk41QTZ3IN88US=> NY\GeWNuW0GQR1XS
NCI-H1993 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknsTWM2OD1{Mj60PVcyKM7:TR?= MXzTRW5ITVJ?
NCI-H1092 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDmTWlKSzVyPUKzMlI5PDNizszN Mo\zV2FPT0WU
RH-1 NGTyT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i1OmlEPTB;MkOuOVM2PyEQvF2= M4TMSXNCVkeHUh?=
DBTRG-05MG M3T4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDDTWM2OD1{Mz64OFczKM7:TR?= NES1V5ZUSU6JRWK=
Mo-T NXm0OnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW3SJlXUUN3ME2yN{46KM7:TR?= MYPTRW5ITVJ?
HD-MY-Z MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\WdIFKSzVyPUK0MlI{PjJizszN NFzGNYRUSU6JRWK=
NCI-H2342 M1\Remdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fmO2lEPTB;MkSuOlc3PyEQvF2= MWXTRW5ITVJ?
C32 NVHSdHNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJ2Lkm1O|Yh|ryP NGr4S25USU6JRWK=
HTC-C3 NHj3[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32wd2lEPTB;MkWuN|U4PyEQvF2= M3;RZXNCVkeHUh?=
NCI-H358 NHvMOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\mc5VEUUN3ME2yOU4{QTR|IN88US=> Ml6yV2FPT0WU
CAL-85-1 M1ThNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC1SZRKSzVyPUK1MlQ2PzdizszN M1OwOXNCVkeHUh?=
HT-1197 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHCTWM2OD1{NT61N|E6KM7:TR?= NXnVUZVsW0GQR1XS
A172 NVXXdJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknvTWM2OD1{NT63NVM3KM7:TR?= MoXLV2FPT0WU
SW1573 NHu0bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ3Lke3PFUh|ryP M{HGSnNCVkeHUh?=
EW-24 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfQTWM2OD1{NT65OlIh|ryP M3nJSXNCVkeHUh?=
SK-MEL-2 M4jCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPabm1KSzVyPUK2MlA{OTJizszN M2XDfnNCVkeHUh?=
LU-65 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHSTWM2OD1{Nj6wOFUzKM7:TR?= MmHjV2FPT0WU
KMOE-2 M4nLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ4LkC5NVUh|ryP M2G2PXNCVkeHUh?=
H-EMC-SS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXwTWM2OD1{Nj60NVE1KM7:TR?= M3H4NXNCVkeHUh?=
H4 NHi3VYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHNSZlKSzVyPUK2MlQzPDNizszN MkH0V2FPT0WU
DU-4475 NEfLUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJ5LkG4O|Ih|ryP MXjTRW5ITVJ?
HCT-116 NGi5ZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\idVBKSzVyPUK3MlQ{PDlizszN MVHTRW5ITVJ?
MSTO-211H MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrWU2xKSzVyPUK3MlYzPTVizszN NFK4VnVUSU6JRWK=
NCI-H292 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\rV5ZCUUN3ME2yO{46PjF5IN88US=> NGjtO|JUSU6JRWK=
NCI-H446 NFTuWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTFPVlbUUN3ME2yPE4zOTB3IN88US=> NYXCSmRYW0GQR1XS
NCI-H2009 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ7LkG0N|Eh|ryP MW\TRW5ITVJ?
MHH-ES-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfmbGNKSzVyPUK5MlM3QDVizszN NG\sPZNUSU6JRWK=
TI-73 NHHsUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP6ToFKSzVyPUK5MlQxODFizszN NXzXTJpoW0GQR1XS
NCI-H2228 NWXTNoIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ7LkS1PEDPxE1? MonwV2FPT0WU
MHH-PREB-1 MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ7LkW1NFUh|ryP M1H6Z3NCVkeHUh?=
ChaGo-K-1 NXTRSnR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PDb2lEPTB;MkmuOlA6PyEQvF2= NWPweYprW0GQR1XS
KY821 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi2Z2VKSzVyPUK5MlY1OzNizszN NWnP[4w{W0GQR1XS
NCI-H209 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ7LkizOlYh|ryP NXrMXG5mW0GQR1XS
NBsusSR MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ7Lkm5NFQh|ryP NY\UclFHW0GQR1XS
NCI-H1304 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XjfmlEPTB;M{CuOVcyPiEQvF2= M3roU3NCVkeHUh?=
NB14 NVXDV3V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNzLkC0OFYh|ryP MnXWV2FPT0WU
HCC1419 M{P3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\WfVNSUUN3ME2zNU4zPCEQvF2= NYH0S4g4W0GQR1XS
KG-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnwNVlkUUN3ME2zNU44PDJ7IN88US=> NW\ZclhnW0GQR1XS
A2780 NV[4bYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjWNolKSzVyPUOxMlg{PThizszN M3TCfnNCVkeHUh?=
NCI-H28 M3[2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXFVphTUUN3ME2zNU46QDZzIN88US=> MnTIV2FPT0WU
C2BBe1 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;6NGlEPTB;M{KuNlY{PCEQvF2= NVPqW|F1W0GQR1XS
VA-ES-BJ MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M162V2lEPTB;M{KuN|Eh|ryP MojjV2FPT0WU
SBC-5 M{i5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonxTWM2OD1|Mj64OVEyKM7:TR?= MXHTRW5ITVJ?
OVCAR-4 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ISmlEPTB;M{OuOFg1QCEQvF2= M3XjNXNCVkeHUh?=
COR-L88 M4SzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPOPFBKSzVyPUO0MlA4PDFizszN MoDzV2FPT0WU
SW954 NUGwTI8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nxWmlEPTB;M{SuNFc2OiEQvF2= MnzKV2FPT0WU
COLO-684 NH;scoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfy[JJKSzVyPUO0MlM1ODRizszN NV6xV|ZMW0GQR1XS
HCC70 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj3TWM2OD1|ND65OVE1KM7:TR?= MXTTRW5ITVJ?
NCI-H1770 M3HXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN2Lkm2NUDPxE1? M3vCd3NCVkeHUh?=
NCI-H1666 NX[yVnU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTN3LkiyOVMh|ryP MYnTRW5ITVJ?
YH-13 NUTNd3A4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXyTWM2OD1|NT65NkDPxE1? MVLTRW5ITVJ?
DJM-1 NUjiVXZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTN4LkiwOFkh|ryP NWjUbGk3W0GQR1XS
KNS-62 MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjNTWM2OD1|Nj65OFM5KM7:TR?= M2Xi[XNCVkeHUh?=
SK-MEL-30 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf1SIFDUUN3ME2zO{45PzN5IN88US=> MXXTRW5ITVJ?
SJRH30 NXTPV252T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN6LkezOFEh|ryP NF7pcWZUSU6JRWK=
GP5d Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSzTWM2OD1|OD64OlU{KM7:TR?= M3u2eXNCVkeHUh?=
SW1116 NX\F[mg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN7LkK4NFUh|ryP NX\GOVVvW0GQR1XS
COLO-800 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorTTWM2OD1|OT6zOlM5KM7:TR?= Mn[3V2FPT0WU
RD NXjOPJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTN7LkWyOVgh|ryP NV;sU2gyW0GQR1XS
NCI-SNU-5 NIO3TIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnzVYFUUUN3ME2zPU43QTF4IN88US=> Mm\UV2FPT0WU
HuO-3N1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TYb2lEPTB;NECuNVA5KM7:TR?= NUTROmprW0GQR1XS
SK-UT-1 NGe2TFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILH[FRKSzVyPUSwMlU3PzRizszN Mli0V2FPT0WU
SK-MEL-3 NETYU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7iOI5tUUN3ME20NE42QTN{IN88US=> NX\O[GR1W0GQR1XS
SK-MEL-28 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\O[2lEPTB;NECuOlQ{PSEQvF2= NYLpPFk{W0GQR1XS
SCC-4 M4XVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PodGlEPTB;NEGuNlE{PyEQvF2= MnnqV2FPT0WU
no-11 NF3McY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT6VYFOUUN3ME20NU44OzV2IN88US=> M2S5SXNCVkeHUh?=
HT-144 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TjeGlEPTB;NEKuNFU3PyEQvF2= NEP0c5RUSU6JRWK=
MFM-223 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf0N5c3UUN3ME20Nk41ODJizszN Mn;WV2FPT0WU
ONS-76 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR{LkiwNVgh|ryP M1O3OXNCVkeHUh?=
ES8 NVP5O5lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnTVmRKSzVyPUSzMlM3QThizszN NY\0Z4E6W0GQR1XS
T-24 M1\We2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nkZ2lEPTB;NEOuOFM3QSEQvF2= NH3PXHVUSU6JRWK=
GAMG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f0R2lEPTB;NEOuOFUyPyEQvF2= NELzXYlUSU6JRWK=
LU-135 M1rzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MluxTWM2OD12ND6wPVI{KM7:TR?= NWPN[ZRYW0GQR1XS
HCC1187 M{[0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m4e2lEPTB;NESuPFI3OiEQvF2= M1TqZnNCVkeHUh?=
TE-1 Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL2TWM2OD12NT6xOlU1KM7:TR?= MWfTRW5ITVJ?
J-RT3-T3-5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\neVFZUUN3ME20OU41OzF3IN88US=> M4\iVnNCVkeHUh?=
GI-ME-N M{n6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR3Lki5OVIh|ryP M4T0NnNCVkeHUh?=
D-392MG Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{CyRWlEPTB;NEWuPVI2PiEQvF2= MnzqV2FPT0WU
KALS-1 NFHpPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r3WmlEPTB;NE[uO|I2PyEQvF2= M3fHXnNCVkeHUh?=
MMAC-SF Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli0TWM2OD12Nj65PVUzKM7:TR?= MYTTRW5ITVJ?
HSC-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XCOWlEPTB;NEeuN|YxQCEQvF2= NYrGNXlFW0GQR1XS
KM-H2 NGnSTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjoTWM2OD12Nz62NFA4KM7:TR?= Ml20V2FPT0WU
LoVo MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jLOmlEPTB;NEiuNVAxOiEQvF2= Mli2V2FPT0WU
NCI-H510A NFTOe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PxfWlEPTB;NEiuNVg4OSEQvF2= MlfWV2FPT0WU
EW-11 NI[1UlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jRSGlEPTB;NEiuNlM1QCEQvF2= NHXPcVBUSU6JRWK=
HCC2998 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTR6Lk[yN|Yh|ryP MkLDV2FPT0WU
J82 NGnTcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR6LkeyOFIh|ryP MYjTRW5ITVJ?
ML-2 M3LJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDrRlhKSzVyPUS5MlQ3ODVizszN Mn[1V2FPT0WU
NCI-H2030 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR7LkexNVch|ryP MmjSV2FPT0WU
NCI-H1792 NGPrNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\5TWM2OD12OT64OVE5KM7:TR?= NEiwcXhUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AMPKα / AMPKα / p-AMPKβ1 / AMPKγ2 / p-LKB1 / LKB1 / CaMKIIβ ; 

PubMed: 23677989     


Dose-dependent analysis of AMPK-related molecules in HCC cells. Cells were exposed to nilotinib at the indicated concentrations for 24 h.

DNMT1 / DNMT3a / DNMT3b ; 

PubMed: 28720666     


Kasumi-1 or MV4-11 cells were treated for 24 h with the indicated doses of nilotinib and subjected western blot analysis to detect the expression levels of DNMT1, DNMT3a, DNMT3b.

pABL1 / p-NF-κB1 / NF-κB / STAT3 / p-STAT3 / IL-1β / IL-6 / COX2 ; 

PubMed: 31396300     


ABL1 regulated the inflammation signaling pathway. Blocking activities of ABL1 with Imatinib and Nilotinib inhibits the inflammatory signaling pathway including activities of NF-κB1, STAT3, IL-1β, IL-6, and COX2.

23677989 28720666 31396300
Growth inhibition assay
Cell viability; 

PubMed: 23677989     


Dose-dependent effects of nilotinib on cell viability. HCC cells were treated with nilotinib at the indicated concentrations for 72 h. Cell viability was measured by MTT assay. Points, mean; bars, S.D. (n = 8). 

23677989
In vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

Protocol

Cell Research:[4]
- Collapse
  • Cell lines: Human primary Schwann and schwannoma cells
  • Concentrations: 1-10 μM
  • Incubation Time: 72 hours
  • Method: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • Formulation: 10% NMP-90% PEG300, PEG300
  • Dosages: 75 mg/kg, 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 529.52
Formula

C28H22F3N7O

CAS No. 641571-10-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04002674 Recruiting Drug: Placebo oral capsule|Drug: Nilotinib Oral Capsule Dementia With Lewy Bodies Georgetown University|National Institutes of Health (NIH) November 2019 Phase 2
NCT03942094 Not yet recruiting Drug: Nilotinib Chronic Myeloid Leukemia Chronic Phase|Nilotinib Shenzhen Second People''s Hospital June 1 2019 Phase 3
NCT03874858 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis March 22 2019 Phase 2
NCT02973711 Suspended Drug: Nilotinib|Drug: Ruxolitinib Leukemia Chronic Myeloid University of Michigan Rogel Cancer Center January 18 2018 Phase 1|Phase 2
NCT03228303 Not yet recruiting Drug: Nilotinib 150 MG [Tasigna]|Drug: Imatinib 400mg Chronic Myeloid Leukemia Assiut University December 1 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • Answer:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Tags: buy Nilotinib (AMN-107) | Nilotinib (AMN-107) supplier | purchase Nilotinib (AMN-107) | Nilotinib (AMN-107) cost | Nilotinib (AMN-107) manufacturer | order Nilotinib (AMN-107) | Nilotinib (AMN-107) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID